 | Up a level |
Berger, Martin Dave; Stintzing, S; Heinemann, V; Yang, D; Cao, S; Sunakawa, Y; Ning, Y; Matsusaka, S; Okazaki, S; Miyamoto, Y; Suenaga, M; Schirripa, M; Soni, S; Zhang, W; Falcone, A; Loupakis, F; Lenz, H-J (2017). Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of oncology, 28(11), pp. 2780-2785. Oxford University Press 10.1093/annonc/mdx412
